Table 3.

Statistical signals for the major safety concerns in the large clinical trials evaluating DPP4i.

Concern	Alogliptin (EXAMINE)	Saxagliptin (SAVOR TIMI 53)	Sitagliptin (TECOS)	Linagliptin (CARMELINA)
Heart failure	No	Yes	No	No
Pancreatitis	No	No	Borderline	Yes
Pancreatic cancer	No	No	No	No

EXAMINE³: Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care; SAVOR-TIMI 53⁵: Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus – Thrombolysis in Myocardial Infarction; TECOS⁴: Trial Evaluating Cardiovascular Outcomes with Sitagliptin; CARMELINA⁸: Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus.

Data were derived from the literature.^3–5,8